IGFBP7 Biomarker for Early AKI Risk Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for predicting acute kidney injury (AKI) during or after surgical procedures or contrast medium administration are inadequate, as they rely on late and nonspecific markers like serum creatinine, which fail to differentiate AKI from chronic kidney disease and do not provide early risk assessment.
Innovation Solution
The method involves determining the levels of the biomarkers IGFBP7 and optionally Cystatin C in a patient's blood or plasma sample before surgery or contrast medium administration, comparing these levels to a reference, and using the results to predict the risk of AKI, thereby aiding in early identification and management.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If serum creatinine is used as a marker for AKI diagnosis, then AKI can be diagnosed, but the diagnosis is delayed and cannot differentiate AKI from CKD
Solution Approach 1:
The patent measures IGFBP7 levels before surgery or contrast medium administration to predict AKI risk in advance. This preliminary assessment allows clinicians to identify at-risk patients before the injury occurs, enabling preventive measures to be taken rather than waiting for creatinine to rise after injury has already happened.
Solution Approach 2:
The patent introduces IGFBP7 as an intermediary biomarker that provides early warning of AKI risk. Unlike creatinine which only reflects established injury, IGFBP7 serves as a mediator that signals impending kidney damage, allowing differentiation between pre-existing CKD and upcoming AKI through baseline comparison.
2Reliability
If current AKI prediction methods are used, then AKI can be identified, but early risk assessment before surgery or contrast medium administration is not provided
Solution Approach 1:
The method performs AKI risk assessment by measuring IGFBP7 levels in the preoperative period or before contrast medium administration. This timing allows sufficient lead time for risk stratification and implementation of preventive strategies before the patient undergoes surgery or receives contrast media.
3Reliability
If serum creatinine levels are monitored, then AKI can be detected, but the marker is nonspecific and cannot differentiate AKI from CKD
Solution Approach 1:
IGFBP7 serves as an intermediary biomarker that provides information about acute kidney injury risk distinct from chronic kidney disease. By measuring IGFBP7 levels before the inciting event (surgery or contrast medium), the method captures information about upcoming acute injury that is not present in baseline creatinine levels, which reflect only chronic status.
Solution Approach 2:
The method utilizes changes in IGFBP7 levels as a parameter to distinguish between AKI and CKD. While creatinine remains relatively stable in CKD patients, IGFBP7 levels change in response to acute insults, providing a dynamic parameter that differentiates acute from chronic kidney conditions.
Data Source
AI summary
The present disclosure describes a method for predicting the risk of a patient to suffer from acute kidney injury (AKI) during or after a surgical procedure or after administration of a contrast medium. The method is based on the determination of the level of the biomarker IGFBP7 (Insulin-like Growth Factor Binding Protein 7) in a body fluid sample obtained from the patient prior to the surgical procedure or prior to the administration of a contrast medium. Further, the present disclosure describes a method for predicting the risk of a patient to suffer from acute kidney injury (AKI) based on the determination of the amount of the biomarker IGFBP7 (Insulin-like Growth Factor Binding Protein 7) and Cystatin C in a body fluid sample obtained from the patient. The present disclosure further encompasses kits and devices adapted to carry out the methods of the disclosed methods.